At Aspen, we are focused on delivering our Purpose, while creating positive, long-term value for our stakeholders and society as a whole.

The Group is well on its way to realising its ambitions to deliver growth and generate stronger shareholder returns.

Performance in this financial year was a critical underwrite in determining our path forward. Our Commercial Pharmaceuticals business had to manage both the headwinds from Chinese volume-based procurement (“VBP”) reductions, and the integration of regional transactions. In addition, our Manufacturing business had to deliver on the promise of a successful roll-out of sterile manufacturing contracts. We have delivered on these key strategic objectives and set a solid foundation for our next period of growth. Our entry into the GLP-1 market offers exciting future opportunities in this growing sector.

The Group has delivered resilient results for the year, absorbing the VBP impact in China and achieving the anticipated stronger performance in H2 2024. Our bolstered product portfolio and increased sterile manufacturing volumes, supported by improved balance sheet metrics, provide a firm foundation for accelerated growth in FY2025 and beyond.